Repligen (NASDAQ:RGEN) Issues FY24 Earnings Guidance

Repligen (NASDAQ:RGEN - Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.50-1.58 for the period, compared to the consensus earnings per share estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million. Repligen also updated its FY 2024 guidance to 1.500-1.580 EPS.

Analyst Ratings Changes

A number of research analysts have commented on RGEN shares. Stephens reaffirmed an "overweight" rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 31st. Finally, Benchmark reiterated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Trading Up 7.0 %

NASDAQ RGEN traded up $9.78 on Tuesday, hitting $149.29. 1,066,870 shares of the company were exchanged, compared to its average volume of 656,426. The company's 50 day moving average price is $141.34 and its 200-day moving average price is $144.87. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market capitalization of $8.36 billion, a P/E ratio of -3,751.75, a price-to-earnings-growth ratio of 4.04 and a beta of 0.96. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.